Although most drugs target proteins, the proteome has remained largely untapped for the discovery of drug targets. The sequencing of the human genome has had a tremendous impact on proteomics and has provided a framework for protein identification. There is currently substantial interest in implementing proteomics platforms for drug target discovery. Although the field is still in the early stages, current proteomic tools include a variety of technologies that could be implemented for large-scale protein expression analysis of cells and tissues, leading to discovery of novel drug targets. Proteomics uniquely allows delineation of global changes in protein expression patterns resulting from transcriptional and post-transcriptional control, post-translational modifications and shifts in proteins between different cellular compartments. Some of the current technologies for proteome profiling and the application of proteomics to the analysis of leukemias by our group are reviewed. Leukemia (2002) 16, 478-485.
Introduction
The spectacular successes in genomics, culminating in the sequencing of the human genome, have had a tremendous impact on proteomics, leading to a resurgence of interest in proteins that represent the most functional compartment encoded for in the genome. The sequencing of the human genome substantially facilitates identification of the protein products of the estimated 30 000 human genes. From a therapeutics point of view, a focus on implementing proteomics platforms for target discovery is well justified, as most drug targets are proteins, not nucleic acids. Assays of gene expression through measurements of RNA do not necessarily predict protein levels. Furthermore, post-translational modifications cause a much greater diversity in protein expression, and they cannot be identified simply by RNA analysis. Additional diversity in expression stems from the various locations in which proteins reside in cells and tissue and the dynamic nature of their translocation between various cellular compartments. Remarkably, the ensemble of drugs currently in use targets no more than a few hundred proteins in the human proteome. Therefore, undoubtedly, the proteome remains vastly untapped from a therapeutics point of view. A comprehensive review of all aspects of proteomics pertaining to therapeutic applications is beyond the scope of this review. In the broadest sense, proteomics encompasses global protein expression profiling, analysis of protein post-translational modifications, protein subcellular localization, protein-protein interactions, elucidation of protein structure, manipulations of protein levels and other approaches to elucidating protein function, all of which being relevant to therapeutics. This review covers approaches to global protein expression analysis and the application of proteomics to the analysis of protein expression in leukemias. Findings pertaining to one protein, Op18, which was identified using proteomics as a major constituent of leukemic cells, and potentially a therapeutic target are presented.
Expression profiling using proteomics
The large-scale profiling of gene expression at the protein level has a long history that predates profiling at the genomic and RNA levels, largely due to the availability of procedures for the two-dimensional (2-D) separation of protein mixtures. 1 Although global protein profile could be determined for tissues and cell populations, difficulties in protein identification limited the utility of such profiling. The more recent ability to predict the sequences of virtually all proteins has provided an important resource for protein expression studies that utilize protein separation technologies. In the past decade, mass spectrometry has facilitated the identification, through sequence database searching, of proteins separated by 2-D gels or other means, at an unprecedented level of sensitivity and speed. 2 The sequencing of the human genome and the emergence of mass spectrometry as an important tool for protein identification have led to a resurgence of interest in protein analysis.
Critical to protein investigations has been the availability of suitable technology for the large-scale analysis of complex protein mixtures that provides high speed and automation, as well as high sensitivity. During the early years of proteomics, the field was largely dominated by a single approach, namely 2-D gels. Initially, the procedure was based on the utilization of carrier ampholytes (CA) in the first-dimension separation. However, more recently, the use of immobilized pH gradients (IPG), has largely surpassed the use of CA. Previously, detailed comparisons of patterns generated for the same cell material in separate laboratories using CA-based 2-D gels was difficult, hampering efforts at establishing collective databases of 2-D gel information. Problems with CA-based separations have included: (1) gaps in the gel patterns resulting from discontinuities in the pH gradient, which varies between sources of CA; (2) drift in the focusing pattern during electrophoresis, particularly severe for basic polypeptides which are underrepresented in 2-D patterns, even when a wide range (pH 3-10) CA gradient is used; (3) difficulty in producing precast gels suitable for 2-D separations. IPG provided an alternative to CA-based separations. The principle of IPG is that the pH gradient is an integral part of the polyacrylamide gel matrix. 3 The IPG 2-D technique overcame many of the problems encountered when using CA. 4 The pH separation range could be defined from broad to extremely narrow ( Figure 1 ). Basic polypeptides could be resolved well, and precast gels could be used. The strip-based IPG 2-D system developed in
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Figure 1
Enhanced protein separations using IPG gradients. Close-up sections covering a 0.5 pH unit span of a standard carrier ampholytebased gel with an effective separation range of 3.5 pH units (a) and IPG gels with separation ranges of 3 (b) and 2 (c) pH units. Note the enhanced resolution of proteins between bars.
our laboratory more than 12 years ago has served as the basis for the current commercially available IPG-based systems. Presently, IPG strips can be purchased from manufacturers, replacing the need to cast slab gels. Several choices of IPG strips with different lengths and pH gradients are currently available.
Subcellular proteomics
A major limitation of current approaches to analyze entire cell and tissue proteomes using separation technologies, particularly with 2-D gels, stems from the difficulty to resolve and quantitate proteins of low abundance. However, selective enrichment for a subset of proteins of interest prior to their separation, further expands the reach of separation technologies to low abundance proteins. Such enrichment can be achieved using a variety of techniques ranging from centrifugation procedures to affinity capture. In addition to reducing sample complexity and increasing sensitivity, strategies based on the separate analysis of subcellular compartments, provide the means to determine protein location in a cell, something that represents an important advantage for proteomics over transcriptomics.
The surface membrane is a compartment of substantial interest with respect to various aspects of cancer, from molecular diagnosis to therapy, as well as for other diseases. For example the ability to define surface membrane antigens, corresponding to defined proteins in hematopoietic malignancies has allowed definitive diagnosis to be readily established in most patients with these malignancies. Additionally, the discovery that the gene for a growth factor receptor (HER2) is amplified in breast cancer and that its protein product is overexpressed on the surface of breast cancer cells, has led to an effective form of therapy in a subset of patients with breast cancer, that includes the use of an antibody that targets HER2. 5 Also, elucidation of the role of growth factor receptors expressed on the cell surface in signaling and uncontrolled cell proliferation, as in the case of epidermal growth factor receptor, has led to the development of new anticancer therapies that target specific components of the EGFR signal transduction pathway. Selective compounds have been developed that target among others, the extracellular ligand-binding Leukemia region of the EGFR. 6 The development of an effective strategy for the comprehensive analysis of membrane proteins would be highly relevant to cancer therapy. Cell surface proteins that are restricted in their expression to specific cancer(s) or that undergo restricted modifications in specific cancer(s) could be relied upon for establishing a diagnosis, for developing a screening strategy for subjects at risk and for monitoring for minimal residual disease or recurrence. Additionally, surface membrane proteins with a restricted expression pattern in cancer could also be utilized for antibody-based therapy, as in the case of HER2 or for vaccine development or for other forms of immunotherapy. Signaling pathways that may be regulated by surface membrane proteins or receptors could also be targeted for a drug-based therapy. Several strategies are currently available to increase the yield in membrane proteins for proteome profiling. 7, 8 Other means to increase sensitivity of proteome profiling include transfer of proteins on to membranes, after 2-D PAGE, followed by probing with protein-specific reagents. For example, we have utilized Western analysis to identify antigenic tumor proteins that induce a humoral response in cancer patients (Figure 2 ). With the heightened interest in the field, the repertoire of technologies and resources available in proteomics has expanded and will likely expand further in the near future. Mass spectrometry initially provided a boost for the 2-D approach by increasing the efficiency of protein identification, when combined with sequence database searching. In fact, the contributions of mass spectrometry to proteomics have extended beyond its synergism with 2-D gels. Mass spectrometry can be utilized for proteomic analysis in combination with separation technologies other than 2-D gels, such as liquid chromatography-based protein separations, and may well have some utility in proteomics as a stand-alone technology. 9 Although currently mass spectrometry is unsurpassed and quite effective in identifying individual proteins, there are some limitations in relying on mass spectrometry alone for global expression profiling, in terms of throughput. Other promising technologies for proteomics include techniques that are independent of both 2-D gels and mass spectrometry. This point is best illustrated by microarray technologies for proteomics, in which either proteins or ligands/antibodies are immobilized at a high density, provid- ing an effective means for quantitative analysis of protein expression and for protein target identification.
Protein microarrays as a tool to probe the human proteome
There is a need to develop technologies for proteomics that allow the systematic analysis of thousands of proteins in parallel for basic biological research, for developing a better understanding of disease processes, and for the identification of novel therapeutic targets. Determination of selective interactions between proteins and many other biomolecules, including other proteins, antibodies, DNA, RNA, drugs and various small ligands are essential for target discovery and validation. Thus, the development of procedures and standardized assays for the simultaneous analysis of protein-directed interactions in a rapid, inexpensive and low-sample-volume format have substantial merit. Recently, several protein microarray methodologies have been developed for the high-throughput investigation of proteins. Some approaches incorporate recombinant proteins obtained using cDNA expression libraries [10] [11] [12] and phage-display libraries. 13 Other approaches array antibodies to specific proteins. [14] [15] [16] [17] [18] [19] [20] [21] In some cases, whole tissuederived samples have been directly arrayed on to slides, to assess reactivity of total protein lysates. [22] [23] [24] A limitation of these methodologies is that proteins undergo numerous posttranslational modifications -phosphorylations, glycosylations, as well as many other modifications -which are critical to their functions, as they can determine activity, stability, localization and turnover. However, these modifications are generally not captured using either recombinant proteins or antibodies that recognize a single form of the protein. We have investigated several approaches to the liquid-based separation of cell and tissue lysates in order to obtain protein fractions with reduced complexity or pure individual proteins. 25 The separation products can be arrayed in a manner that allows probing cell and tissue-derived proteins to uncover specific targets. For example, using a combination of anion exchange and reverse phase LC, we estimated that some 600-1200 individual protein fractions could be readily obtained and utilized for array analysis from whole cell lysates. Fractions that react with specific probes are well within the reach of mass spectrometric techniques for identification of their constituent proteins and of chromatographic and gel-based separation techniques for resolving their individual protein constituents. The LC procedures allow sufficient protein amounts to be resolved for the construction of large numbers of microarrays from a given cell or tissue source. We have studied different types of microarray surface binding chemistry with respect to their potential to achieve the highest level of sensitivity in different assays. Individual fractions from whole cell lysates were arrayed on to glass slides and tested as probes to detect the binding of specific antibodies to their corresponding antigens in arrayed lysate fractions. Typically poly-L-lysine surfaces react with the amine residues on the surface of the arrayed proteins to form covalent urea linkages, and with the surface carboxylic acid groups to produce an amide bond. The binding chemistry of the amine-coated slides gave poor results in our hands. A slight improvement was achieved with the use of slides that had been treated with an aldehyde-containing silane reagent. Aldehydes promptly react with primary amines on the protein surface (lysines and ␣-amine at their NH 2 -ends in most cases) to form a Schiff's base. The same assays on nitrocellulose membrane covered slides showed that adjacent fractions containing lower levels of antigen could also be detected, whereas the aldehyde microarrays were not able to display them. Antibody/antigen interactions were detected by measuring the fluorescence emission of the labeled antibody when attached to its corresponding antigen.
In some experiments, aliquots from 20 Rotofor fractions of whole cell lysates were arrayed on to nitrocellulose slides. The SPOTLIGHT strategy used for protein microarrays was based on the technology developed for DNA microarray. 26, 27 Each slide was hybridized with a different primary antibody against a specific antigen. The reactive fractions were highly concordant with fractions shown to be reactive by Western blot analysis (Figure 3) . The intensity of the fluorescent signal varied in an interdots fashion, reflecting likewise the different proportions of the specific detected protein, in relation to the total amount of protein in each fraction. The analysis showed a high signalto-noise ratio, which provides excellent sensitivity and reproducible detection. The findings were also concordant with dot-blot controls, run in parallel and developed with the ECL chemiluminescence technology.
One of the limitations of using nitrocellulose slides is the inability to control protein orientation during the immobilization process. The necessity of optimizing the interactions between immobilized macromolecules, eg antigens, antibodies, peptides, and their corresponding target ligands in solution, as well as with the solid device interface has been recognized. 28, 29 Numerous procedures are currently available for oriented immobilization: ionic interaction, specific covalent binding, apoenzyme reconstituted on the surface that binds to a prosthetic group, receptor/ligand interactions, specific affinity motifs engineered on the surface of the protein, etc. In most cases it has been shown that optimal binding of protein to solid supports requires hydrophilic spacers. 30 The coupling of technologies for protein separation with techniques for orientational control would permit different surfaces of the proteins to interact with other proteins or ligands and enhance efficiency of binding. 
Leukemia
Proteomic profiling of acute leukemia
One source of novel therapeutic targets that may emerge from proteomics consists of proteins with distinctive characteristics with respect to their expression patterns, uncovered through global profiling of protein expression. With the recent interest in the use of microarrays to molecularly characterize normal and diseased tissues based on differential gene expression, it is of interest to note that efforts to do the same using proteomics have been attempted as long as two decades ago. This is illustrated by our investigation of the different subtypes of acute lymphoid leukemias in the 1980s using proteomics. 31 We utilized 2-D PAGE to identify polypeptide differences due to lineage among lymphoblasts obtained directly from peripheral blood or bone marrow of children with acute lymphoblastoid leukemia (ALL). The specific objectives were (1) to identify polypeptides that were limited in their occurrence to only a subset of the patients with ALL; (2) to relate the presence of these polypeptides to immunologic and other previously established markers, and (3) to attempt to identify the cell of origin of CALLA-negative non-T-cell, non-B-cell ALL. Among some 400 polypeptides that were analyzed, 12 polypeptide were detected that could distinguish between the major subgroups of ALL and between ALL and acute myelogenous leukemia (AML). 31 These included a new marker for common ALL and markers for cells of B and T lineages. Analysis of the 2-D patterns also allowed the tentative identification of T-cell lineage in some cases with an otherwise undifferentiated non-T-cell non-B-cell phenotype. 2-D PAGE thus provided a powerful tool for the delineation of the cell of origin in leukemia. In separate studies, polypeptide markers were detected
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Leukemia in 2-D gels that indicated a myeloid origin of blasts obtained from children who presented with acute leukemia, the cells of origin of which could not be determined at the time of diagnosis, by morphologic, cytochemical or immune marker analysis. 32 Clinical studies have shown that among children with ALL, age at diagnosis is an important prognostic indicator. 33, 34 Infants less than 1 year of age at the time of diagnosis had the worst outcome. We analyzed the polypeptide patterns of leukemic cells of infants and older children with ALL using 2-D PAGE. Distinct levels of a polypeptide, designated L3 were observed between infants and older children with otherwise similar cell surface markers. 35 There was much difficulty in the 1980s to obtain sufficient sequence information for polypeptides of interest, detected in 2-D gels, to allow their identification. Identification could be undertaken therefore for only a limited number of proteins and with much effort. The new marker we described for common ALL was successfully sequenced resulting in its identification as heat shock protein Hsp27, which was found to be constitutively expressed at high levels in common ALL. 36 The polypeptide marker that distinguished between infant ALL and ALL of older children was found to be a phosphorylated form of Hsp27. Illustrative of the unique contributions of proteomics to profiling post-translational changes was the finding that phosphorylation of Hsp27 was reduced in the infants compared to older children with ALL. 35 Other studies that have investigated correlations between protein expression profiling and clinical data in leukemia include comparisons between protein expression patterns obtained by 2-D gels of different patients with B cell chronic lymphocytic leukemia (B-CLL) and correlations of pattern variability with clinical variability. 37 Proteins were identified that clearly discriminated between patient groups with defined chromosomal characteristics or whose expression levels correlated with clinical parameters, such as patient survival. The data obtained showed that B-CLL patient populations with shorter survival times exhibited changes in the levels of redox enzymes, heat shock protein 27 and protein disulfide isomerase. These proteins may potentially play a role in the response to leukemia therapy.
High level expression of Op18 in acute lymphoid leukemias
Another polypeptide we identified in our leukemia studies was Oncoprotein 18 (Op18). Analysis of ALL 2-D patterns revealed strikingly high levels of a protein, which we designated Op18, compared to the levels of this polypeptide in non-leukemic resting or proliferating lymphoid cells. Op18 levels were also increased in AML, but to a lesser extent. Partial amino acid sequence analysis of Op18, facilitated our ability to clone the gene. 31, [38] [39] [40] Interestingly, in a recent DNA microarray-based study of leukemias, Op18 was identified as one of the discriminators between ALL and AML. It should be noted that whereas with RNA based analysis, Op18 generates one measure, namely that of the levels of its corresponding RNA, at the protein level there is the potential of analyzing separately the different post-translationally modified forms of Op18. Op18 occurs in phosphorylated and unphosphorylated forms (Figure 4) . For example, analysis of neuroblastoma 2-D patterns uncovered diminished phosphorylation of Op18 in aggressive neuroblastomas in which the N-myc oncogene is frequently amplified. 41 We have determined the levels of unphosphorylated Op18 and of its major phosphorylated forms, Op18a and Op18b,
Figure 4
Western blot analysis of Op18 isoforms. Proteins from solubilized tissue were separated by 2-D PAGE. Only the close-up sections framing Op18 protein are shown. Arrows point to unphosphorylated forms of Op18 (labeled Op18, Op18* and Op18', respectively), a major isoform (Op18a) which is phosphorylated on one of the four phosphorylatable serine residues and several minor isoforms which are phosphorylated on several serine residues (Op18b, c and d, respectively). The unphosphorylated mutant form of Op18 is dictated as M-Op18, and its major phosphorylated (on a single serine residue) isoform is indicated as M-Op18a. Interestingly, minor isoforms of M-Op18 that were phosphorylated on several serine residues were not observed.
in a series of 177 childhood acute leukemias by means of quantitative 2-D PAGE. Op18 phosphorylation was significantly correlated with the white blood count at the time of diagnosis, and with a high percentage of cells in the S phase. Our findings suggested that strategies to inhibit Op18 expression or phosphorylation may be effective in inhibiting leukemia cell proliferation.
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Op18 has been shown to destabilize microtubules in vitro, at least in part due to tubulin sequestration and microtubule catastrophe-promoting activities. [43] [44] [45] [46] Op18 is expressed in proliferating cells of most cell lineages 47 and its level increases significantly during the S phase of the cell cycle. 48, 49 The functionality of Op18 is also tightly controlled by phosphorylation during the cell cycle, 50 with its activity being down-regulated by increased phosphorylation on four serine (S16, S25, S38 and S63) residues. 46, 51 Higher order phosphorylation is a prerequisite for progression through mitosis. Mono-and bi-phosphorylated Op18 isoforms are most abundant in cells during the S phase, and the tri-phosphorylated Op18 isoform is predominant in G2/M. 50, 52, 53 In vitro, S25 and S38 are targets of MAP kinases. Cyclin-dependent kinases phosphorylate Op18 on S25 and S38. 52, 54 S16 is the target for the Ca 2+ /calmodulindependent kinases II and IV/Gr. 55 S63 and S16 are substrates for cAMP-dependent protein kinases. 52, 56 Being a substrate of several kinase families, Op18 has been proposed to act as a relay phosphoprotein for multiple signal transduction pathways. 57 The importance of Op18 phosphorylation in cell cycle progression was demonstrated by using transfectants expressing 483 SPOTLIGHT a phosphorylation site-deficient mutant form of Op18 (in which the four phosphorylatable serine residues were replaced with alanines (4A mutant)). Overexpression of this mutant prevented formation of a normal mitotic spindle and led to G2/M arrest and subsequent polyploidization. 51, 58 The 4A non-phosphorylatable mutant simulates the active form of Op18, suggesting that down-regulation of Op18-mediated microtubule-destabilizing activity is required for spindle formation and mitotic progression. Indeed, although overexpression of wild-type phosphorylatable Op18 destabilized interphase microtubules, it did allow for proper spindle formation and normal progression through the cell cycle. The involvement of Op18 in spindle formation appears to function through an interaction with tubulin dimers that regulate microtubule dynamics.
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Op18 mutation
Given its role as an important regulator in proliferation and differentiation, deregulated expression of Op18 may be relevant to cancer. Indeed, an increased Op18 expression at both RNA and protein levels has been reported in a variety of cancers. 41, [59] [60] [61] [62] We have identified a somatic Q18E mutation in Op18 in an esophageal adenocarcinoma. 63 Functional analyses of this mutation demonstrated that the mutant Op18 has transforming properties. As part of a proteomic analysis of esophageal adenocarcinomas, 2-D PAGE was undertaken for 17 tumors and their corresponding normal and dysplastic (Barrett's) tissue. Interestingly, one tumor showed a lack of the major Op18 isoform by 2-D PAGE, as well as the appearance of a novel neighboring protein spot. The novel protein was absent in normal and dysplastic esophageal tissue from the same patient (Figure 4 ). This novel protein was not present in the normal, dysplastic or tumor tissues of the other 16 patients analyzed. This novel protein was recognized by an anti-Op18 antibody, indicating a potential somatic mutation(s) in Op18. PolyA + RNA was isolated from the tumor and subjected to RT-PCR to amplify the Op18 cDNA. A substitution of a G for C was detected at nucleotide 155 in the Op18 cDNA, which results in a Q18U⇐E substitution at the protein level. To further investigate the biological significance of the Op18 mutation, the wild-type (S-Op18), mutant Op18 (M-Op18) and anti-sense (AS-Op18) cDNA were transfected into the NIH/3T3 cell line and allowed to integrate into the cell genome. Upon reaching confluence, the M-Op18 infectants, but not S-Op18, nor with infectants expressing anti-sense of Op18 (AS-Op18) and vector-only controls were observed to form large numbers of foci. We also observed efficient colony formation in soft agar only with cells expressing M-Op18. We determined the ability of cells expressing M-Op18 to form tumors in SCID mice. Tumors greater than 5 mm in diameter were observed within 21 days in 10/10 mice inoculated with M-Op18. No tumors were observed in the 10 mice inoculated with S-Op18 cells.
As the unphosphorylated form of Op18 has been shown to bind and stabilize microtubules in vivo, we explored whether addition of various concentrations of Paclitaxel, which in sufficient concentration causes a G2/M blockage of the cell cycle, would further perturb cell cycle progression of M-Op18 as compared with S-Op18. In the absence of Paclitaxel, we observed a doubling of the percentage of M-Op18 cells in G2/M as compared to S-Op18, indicating that the retardation of doubling times observed in the M-Op18 cell population most likely resulted from a G2/M cell cycle stage-specific Leukemia blockage. Taken together, our results suggested that expression of the mutated form of Op18 may enhance stability of microtubules through the cell cycle. This may, in turn, led to the accumulation of M-Op18 at the G2/M stage of the cell cycle.
Op18 as a therapeutic target
The Op18 findings to date, suggest that manipulation of Op18 expression and/or activity may have some therapeutic benefit. We previously demonstrated that inhibition of Op18 expression in leukemic cells resulted in growth retardation. 64 Studies by others have shown that antisense inhibition of Op18 expression in leukemic cells resulted in growth arrest at a lower saturation density, loss of serum independence, and loss of anchorage-independent growth in vitro. 65 In addition, inhibition of Op18 expression resulted in a marked inhibition of tumorigenicity of leukemic cells in vivo in the severe combined immune deficiency mouse model. These studies demonstrated that a high level of Op18 expression in leukemic cells was necessary for the maintenance of the transformed phenotype and suggested that Op18 may be a potential target for antileukemic interventions.
In other studies, Op18 overexpression has been shown to increase the sensitivity of human lung carcinoma cells to vindesine. 66 Antimitotic agents that bind to tubulin have been used for chemotherapy to treat various malignancies. Op18 cDNA was transfected to SBC-3 human lung carcinoma cells, and stable transfectants were isolated. The sensitivity of these transfectants against antimitotic agents was examined by the MTT assay in vitro. Op18-transfected cells showed higher sensitivity to vindesine and vincristine, but not to taxanes. Vindesine exposure increased the G2/M population of the cell cycle in the mock transfectants, but not in sense transfectants. Thus Op18 expression was associated with lung carcinoma cell sensitivity to vindesine.
In other studies, inhibition of Op18 expression resulted in increased sensitivity to the antimitotic effects of okadaic acid. 67 This was reflected by increased growth inhibition associated with mitotic arrest. A vast majority of the Op18-inhibited cells were found to be arrested in late metaphase/anaphase and had severe mitotic spindle abnormalities. Exposure to okadaic acid also resulted in a bigger ratio of polymerized/unpolymerized tubulin in Op18-inhibited cells relative to control cells. Op18 is representative of proteins that may be uncovered using proteomics and that may represent novel drug targets. Drugs that affect Op18 levels, cellular location, phosphorylation status or ability to interact with tubulin may have an effect on the ability of tumors cells to proliferate.
Perspective
It is likely that no one technology platform will allow the complete profiling of the wide range of proteins that occur in a cell or tissue. The two approaches presented in this review, namely the use of gel-based 2-D separations of proteins and the use of microarrays of human cell-derived proteins may need to be complemented with other approaches. These may include non-gel-based protein separations followed by mass spectrometry, direct mass spectrometric analysis of digests of protein fractions of limited complexity, and antibody-based microarrays, to name just a few. Furthermore the technologies
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Leukemia utilized for discovery of novel protein targets may well be different from technologies for target validation. Once a protein with a potentially interesting expression pattern is identified, validation of its expression pattern may rely on other platforms such as tissue microarrays that allow the simultaneous analysis of its expression pattern and subcellular localization in hundreds of tissue samples with a directed antibody.
It is too early at the present time to assess the contribution of proteomics, as opposed to other approaches such as transcriptomics, to the identification of novel therapeutic targets. A major challenge in proteomics is going to be the development of effective means for delineating post-translational modifications in proteins. Currently much interest is focused on strategies for the analysis of phosphoproteins and glycoproteins. A recent special issue of the journal Proteomics is devoted to protein post-translational modifications. 68 As data accumulate with respect to the expression pattern of the proteins encoded for by the approximately 30 000 human genes, the mining of the proteome, be it for drug target discovery or for other applications, necessitates the storage and querying of large sets of data. Such data may reside in a variety of specialized data sources that support various aspects of genomics, proteomics and drug design. Data from one source may need to be combined with data from other sources. The ability to effectively integrate proteomics data with other types of data will be highly relevant to various aspects of drug discovery. Systems that offer such capabilities are currently under development.
